CalciMedica, Inc. (NASDAQ:CALC) Sees Large Growth in Short Interest

CalciMedica, Inc. (NASDAQ:CALC) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 24,800 shares, a growth of 5.1% from the August 31st total of 23,600 shares. Based on an average daily trading volume, of 55,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.6% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Oppenheimer lifted their price target on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th. Singular Research raised CalciMedica to a “moderate buy” rating in a research note on Friday, June 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of CalciMedica in a research note on Tuesday, August 13th.

Insider Buying and Selling

In other CalciMedica news, Director Robert N. Wilson acquired 54,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were acquired at an average price of $3.72 per share, with a total value of $200,880.00. Following the purchase, the director now owns 364,196 shares of the company’s stock, valued at approximately $1,354,809.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have acquired 65,000 shares of company stock valued at $243,120. 53.30% of the stock is owned by company insiders.

CalciMedica Stock Performance

NASDAQ:CALC opened at $4.23 on Wednesday. CalciMedica has a 52-week low of $1.75 and a 52-week high of $8.38. The company has a market cap of $45.47 million, a P/E ratio of -1.97 and a beta of 1.27. The stock’s 50-day simple moving average is $4.39 and its 200 day simple moving average is $4.65.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.03. As a group, equities analysts predict that CalciMedica will post -2.21 earnings per share for the current fiscal year.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.